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ALLERGIC RHINITIS
Definition
Rhinitis is defined as the presence of at least one of the follow-
ing: congestion, rhinorrhea, sneezing, nasal itching, and nasal 
obstruction.
1,2 Other reported symptoms include throat clearing, 
headaches, facial pain, ear pain, itchy throat and palate, snoring, 
and sleep disturbances.
3,4 A system of rating symptom severity 
has been developed using a 7-point visual analog scale that in-
cludes elements of nasal symptoms, non-nasal symptoms, and 
the effects of medications. (See reference for copies of assess-
ment forms).
5 Allergic rhinitis is present when these symptoms 
are triggered by an allergen. Perennial allergic rhinitis is most 
often attributed to dust mites, mold spores, and animal dander, 
whereas seasonal allergic rhinitis is attributed to a large variety 
of pollens that varies based on geographical region.
2
Epidemiology
Allergic rhinitis is very common condition throughout the 
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world.
6 In the United States it affects between 10-30% of the 
adult general population and up to 40% of children. This ac-
counts for 30-60 million people in the United States
1 and the 
prevalence has been increasing in recent decades,
2 making it 
the fifth most common chronic disease in the US.
7 Risk factors 
include an atopic family history, IgE levels above 100 IU/mL 
before the age of 6 years, higher socioeconomic status, and pos-
itive epicutaneous allergen testing.
1 However, 44-87% of people 
with rhinitis have mixed allergic and non-allergic rhinitis,1 and 
therefore all that sneezes is not necessarily purely allergic in eti-
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Rhinitis is a global problem and is defined as the presence of at least one of the following: congestion, rhinorrhea, sneezing, nasal itching, and nasal 
obstruction. The two major classifications are allergic and nonallergic rhinitis (NAR). Allergic rhinitis occurs when an allergen is the trigger for the 
nasal symptoms. NAR is when obstruction and rhinorrhea occurs in relation to nonallergic, noninfectious triggers such as change in the weather, ex-
posure to caustic odors or cigarette smoke, barometric pressure differences, etc. There is a lack of concomitant allergic disease, determined by neg-
ative skin prick test for relevant allergens and/or negative allergen-specific antibody tests. Both are highly prevalent diseases that have a significant 
economic burden on society and negative impact on patient quality of life. Treatment of allergic rhinitis includes allergen avoidance, antihistamines 
(oral and intranasal), intranasal corticosteroids, intranasal cromones, leukotriene receptor antagonists, and immunotherapy. Occasional systemic corti-
costeroids and decongestants (oral and topical) are also used. NAR has 8 major subtypes which includes nonallergic rhinopathy (previously known as 
vasomotor rhinitis), nonallergic rhinitis with eosinophilia, atrophic rhinitis, senile rhinitis, gustatory rhinitis, drug-induced rhinitis, hormonal-induced 
rhinitis, and cerebral spinal fluid leak. The mainstay of treatment for NAR are intranasal corticosteroids. Topical antihistamines have also been found 
to be efficacious. Topical anticholinergics such as ipratropium bromide (0.03%) nasal spray are effective in treating rhinorrhea symptoms. Adjunct 
therapy includes decongestants and nasal saline. Investigational therapies in the treatment of NAR discussed include capsaicin, silver nitrate, and 
acupuncture.
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ology.
While many patients downplay rhinitis symptoms as an in-
convenience rather than a disease, the economic burden is 
quite significant. In the United States, the direct medical costs 
(physician services, diagnostics, medications, etc.) nearly dou-
bled from US$6.1 billion in 2000 to US$11.2 billion in 2005.
8 In 
Europe, it was estimated that by the late 1990s, €1.0-1.5 billion 
were spent on direct costs.
2 Additionally, the indirect costs (trav-
el for physician visits, decreased work productivity, missed 
school and loss of parents’ pay from missed work to care for 
their children, etc.) are also considerable. In the US, there are 
3.5 million lost workdays and 2 million lost school days due to 
allergic rhinitis. It is estimated that productivity decreases by 
US$600 per affected employee per year, which is a greater loss 
than asthma, diabetes, and coronary heart disease. Overall, al-
lergic rhinitis was the fifth costliest chronic disease in the Unit-
ed States with 75% of the costs coming from decreased produc-
tivity.
4,8 The indirect costs in Europe were estimated to be more 
than the direct costs at €1.5-2.0 billion.
2
Pathophysiology
Cellular signals
Allergic rhinitis is an IgE-mediated disease resulting in inflam-
mation of the nasal mucosa. Allergic patients have increased 
levels of allergen specific IgE in their nasal mucosa compared 
to controls. Histamine release from resident mast cells is a ma-
jor mediator in the inflammation of allergic rhinitis. Eosinophil-
ic inflammation also plays an important role. A Th2 response 
ensues with the release of IL-4 and IL-5. Recently, thymic stro-
mal lymphopoietin (TSLP), IL-25 (or IL-17E), and IL-33 have 
also been implicated. As eosinophils produce IL-5 and granu-
locyte macrophage-colony stimulating factor (GM-CSF), they 
perpetuate their own survival. After allergen exposure, rhinitis 
can persist for several weeks.
2,9 There is an immediate and a late 
phase to allergic rhinitis. Both are characterized by the same 
symptoms, but the late phase’s predominate symptom is nasal 
congestion. Eosinophils release mediators that can induce tis-
sue damage, and pre-treating with topical glucocorticoids re-
duces eosinophil infiltration and cytokine release.
1
Neuronal aspects
The interplay between sensory nerve fibers and the efferent 
sympathetic and parasympathetic neurons helps to regulate 
the mucosal barrier of the nasal epithelium. The thinly myelin-
ated Aδ fibers convey the sensations of pain and cold to the 
central nervous system. A thick mucosal lining decreases the 
ability of these neurons to sense passing airflow, which contrib-
utes, to the sensation of nasal obstruction and dyspnea. When 
menthol receptors on these nerves are stimulated, the result is 
a false sense of nasal patency and less dyspnea. After the initial 
rapid stimulation of Aδ fibers, a delayed activation of the non-
myelinated slowly conducting C fibers ensues. In addition to 
multiple allergens, the C fibers can be stimulated by nicotine, 
cigarette smoke, aldehyde, formaldehyde, isocyanates, sulfur 
dioxide, and other toxicants. Capsaicin is the naturally occur-
ring substance in spicy peppers that induces the sensation of 
heat, and it activates transient receptor potential and ion chan-
nel proteins (TRPs). A stinging sensation similar to that induced 
by capsaicin occurs when the osmotic tonicity rapidly changes 
at the cellular surface. This can happen when dry pollen and 
dust grains land on mucosal surfaces, causing water to efflux 
from epithelial cells.
Acetylcholine is released from parasympathetic nerve fibers 
that innervate glands and vessels of the airway mucosa. Eosin-
ophils interfere with the activation of the presynaptic M2 mus-
carinic receptor, which decreases the negative feedback on ace-
tylcholine release. The result is an increase in bronchoconstric-
tion and glandular secretion. To balance the effects of the para-
sympathetic nervous system, sympathetic neurons induce va-
soconstriction in the epithelium. Stimulation of α-adrenergic 
receptors by nasal decongestants (discussed below) reduces 
mucosal thickness.
The nociceptive C fibers innervate glands and deep subepithe-
lial vessels. Their release of substance P may lead to increased 
expression of E-selectin and VCAM on endothelial cells. The re-
sult is increased infiltration of leukocytes, which is a critical part 
of the late-phase response of allergic rhinitis. Interestingly, when 
substance P is administered to allergic individuals, mRNA lev-
els of IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, TNFα, and γ-interferon vs. 
only an increase of IL-6 and IL-6 mRNA in non-allergic individ-
uals. Neural plasticity also comes into play in allergic subjects. 
This occurs when persistent stimulation from allergens increas-
es the sensitivity of involved neurons to depolarize. Allergic in-
dividuals’ neurons will depolarize in the presence of bradykinin 
and endothelin, whereas these substance induce no response in 
non-allergic subjects.
Because it is more difficult to localize visceral compared to 
peripheral sensations, the activation of nerve fibers that inner-
vate deep tissues often results in referred pain. Sinus headaches 
are a common example. Noxious stimulation of the inferior tur-
binate induces the sensation of pain in the maxillary teeth, zy-
goma, and eyes. The middle turbinates refer pain to the temple, 
zygoma, inner canthus, and forehead.
10
Genetics
Monozygotic twins show a concordance of 45-60% in the de-
velopment of allergic rhinitis, and dizygotic twins have a con-
cordance rate of about 25%. These data point to a genetic link. 
However studies into the genetics of allergic rhinitis are lacking, 
and current findings are preliminary. Chromosome 3 has three 
regions linked to allergic rhinitis, 3q13, 3q13.31, and 3p24. A 
possible involved region on chromosome 4 is 4q24-q27. Cer-
tain single nucleotide polymorphisms (SNPs) have been impli-
cated GATA3 and IL-13.
9 Specific HLA haplotypes have been Tran et al.
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associated with allergic responses to particular allergens. This 
may be due to more than just an association since HLAs pres-
ent antigens to T-cells. There is also evidence that points to ge-
netic associations of the T-cell receptor (TCR) α-chain and the 
high affinity IgE receptor FcεRI with increased allergy. Other 
candidate genes for further investigation include those involved 
with the production of IgE, IL-4, IL-5, and IL-13.
11
Treatment
Avoidance
Since allergic rhinitis is induced by specific allergens, it makes 
sense that avoiding those triggers would be an effective treat-
ment. However, this is not always possible as in the case of pol-
lens, and for those with mixed allergic and non-allergic rhinitis, 
avoidance will not completely alleviate their symptoms. Some 
allergens can and should be avoided as the severity of rhinitis 
correlates with the levels of allergens in the environment. Pre-
cautions can be taken against dust mites. Carpet removal, re-
moval of soft toys from the bedroom, using allergen-imperme-
able bedding covers for the mattress and pillow, vacuuming 
with a high-efficiency particulate air (HEPA) filter, and washing 
bedclothes and bed sheets in hot water (60°C) are helpful. Any 
single method alone is unlikely to provide benefit, and patient 
should be encouraged to use multiple interventions. For those 
with animal allergies, ideally, removal of the pet from the home 
would be best along with careful vacuuming of all carpets, up-
holstered furniture, and mattresses. It may be impossible to 
clear cat dander or take up to 20 weeks for cat dander levels to 
decrease to cat free homes. Isolating the pet to a single room 
and using a HEPA filter is a second best option. Studies have 
been inconsistent on the benefits of regular bathing of cats.
1,2 
Spaying or neutering cats and dogs increases levels of their ma-
jor allergens found in homes, Fel d 1 and Can f 1 respectively. 
Having fewer pets correlates with lower dander levels. Interest-
ingly, keeping cats outside does not significantly reduce the 
presence of Fel d 1, while the less access dogs have to the home 
and bedroom correlates with lower amounts of Can f 1 found in 
the bedroom.
12,13 Environmental moisture control can improve 
mold levels. Using pesticides and meticulous control of food 
debris can decrease cockroach environmental allergens. How-
ever, it may take over 6 months to remove residual cockroach 
allergen.
1
Antihistamines
Histamine activates the H1 receptor on a distinct set of neu-
rons to produce the sensation of itching. This leads to sneezing, 
nose rubbing, and the “allergic salute.”
10 H1-antihistamines are 
inverse agonists, rather than H1-antagonists, that combine with 
and stabilize the inactive form of the H1 receptor leading toward 
a shift in equilibrium to the inactive state. In addition to the in-
verse agonist effect at the H1 receptor, the newer second-gener-
ation agents have both anti-allergic and anti-inflammatory 
properties.
The first generation H1 antihistamines such as diphenhydr-
amine, chlorpheniramine, brompheniramine and hydroxyzine 
are also referred to as the sedating antihistamines. These agents 
are effective at controlling the rhinorrhea, sneezing and pruri-
tus associated with allergic rhinitis. Unfortunately these agents 
cross the blood-brain barrier thus producing undesirable side 
effects such as central nervous system depression, sedation 
leading to impaired performance at home, work and school 
and cardiotoxicity. There are no long-term safety studies on the 
first generation antihistamines. These agents have poor H1 re-
ceptor selectivity and act on muscarinic receptors causing anti-
cholinergic effects such as dry mouth, urinary retention, consti-
pation and tachycardia. The second-generation antihistamines 
developed in the early 1980’s, have improved H1 receptor selec-
tivity, absent or decreased sedation, faster onset and longer du-
ration of action and fewer adverse effects. Their half-lives are 
longer (12-24 hours) compared to the first generation (4-12 
hours).
14 Of the second generation H1-antagonists, fexofenadine 
has no sedating effects even at higher than recommended dos-
es. Loratadine and desloratadine are non-sedating at recom-
mended doses but may cause sedation at higher doses. Cetiri-
zine, and its purified enantiomer levocetirizine, have more se-
dation potential that other second generation H1-antagonists.
15 
All rhinitis symptoms, except for obstruction, can be alleviated 
by H1-antihistamines, and there does not seem to be a superi-
ority of any one of the second generation H1-antihistmines over 
another. 
Topical H1-antihistamines (azelastine, olopatadine) provided 
faster onset of action (less than 15 minutes) and similar to great-
er efficacy compared to oral preparations in regard to rhinitis 
and conjunctivitis. There has even been an association with im-
provement of congestion. However, their results are limited to 
the local organ effects, and require twice daily use to maintain a 
sustained response; whereas second generation oral H1-antag-
onists can be taken on a daily basis. Some patients may com-
plain of a bitter taste, and intranasal H1-antagonists are less ef-
fective than intranasal steroids.
1,2 In a direct comparison trial 
between azelastine nasal spray versus oral cetirizine, azelastine 
was found to have a significant improvement in nasal symptom 
scores for the specific symptoms of sneezing and nasal conges-
tion over cetirizine.
16
Steroids
In addition to oral H1-antihistamines, intranasal corticoste-
roids are a mainstay of treatment. They are the most effective 
medications for controlling all rhinitis symptoms. Their onset of 
action is from 3-12 hours. Their use on an as needed basis is not 
as effective as continual use
1 but may not be required continu-
ally in all patients. They are generally safe, and there is little evi-
dence to support suppression of the hypothalamic-pituitary-
adrenal axis with prolonged use. Side effects are generally mild Management of Rhinitis: Allergic and Non-Allergic
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(crusting, dryness, and minor epistaxis). They can be minimized 
by proper nasal spray technique. Septal perforation has only 
been described anecdotally.
2 For patients whose symptoms are 
not optimally controlled with intranasal steroids, adding an in-
tranasal (but not oral) antihistamine may give some additional 
benefit.
3
Systemic corticosteroids should be considered a last resort 
treatment option, but they may be necessary for severe or in-
tractable symptoms. If they are used, then oral is preferred over 
parenteral because of the lower risk of systemic side effects and 
the ability to adjust doing. Steroids should never be injected 
into the turbinates. Recommendations on short courses oral 
steroids differ from 5-7 days
1 to no more than 3 weeks.
2
Decongestants
Decongestants are also available in oral and topical formula-
tions. They are effective in relieving congestion. However, stud-
ies of H1-antihistamine in combination with oral decongestants 
failed to show improved benefit compared to either alone. Side 
effects include insomnia, anorexia, irritability, and rarely ele-
vated blood pressure. Oral decongestants should be avoided in 
children less the 1-year of age, adults over 60 years of age, and 
any patient with a cardiac condition. The main side effect of 
topical decongestants is the development of rhinitis medica-
mentosa, which can appear in some patients after only 3 days 
of use or not at all in other patients after six weeks of use. Euro-
pean guidelines recommend a maximum of 10 days use.
1,2
Cromones
Intranasal formulations of cromolyn and nedocromil have 
been used to treat allergic rhinitis but are less effective than 
topical corticosteroids. It is believed that cromones are less ef-
fective than topical antihistamines,
2 but adequate comparative 
studies have not been performed.
1 Although the exact mecha-
nism is unknown, they work mainly by inhibiting mast cell acti-
vation. Studies have shown that nedocromil inhibits the activa-
tion of neutrophils, eosinophils, monocytes, and macrophages 
as well. There may even be an inhibitory effect on neural sig-
nals involved in rhinitis.
2 Overall, they are safe with minimal to 
no side effects.
1,2
Miscellaneous 
The anticholinergic ipratropium bromide is available in a na-
sal form and blocks the parasympathetic signaling that leads to 
watery rhinorrhea, and it has been shown effective in control-
ling this particular symptom. There are little to no side effects. 
Guidelines state it does not decrease sneezing or nasal obstruc-
tion,
1,2 but one study in children showed improvement in rhi-
norrhea, congestion, and sneezing although to a lesser degree 
than intranasal steroids.
17
Leukotriene receptor antagonists have been shown to be ef-
fective controlling allergic rhinitis, and they are comparably ef-
fective with oral antihistamines.
1 After 2 weeks of therapy, mon-
telukast progressively decreased symptoms scores, but still to a 
lesser degree than intranasal fluticasone.
18 For patients whose 
symptoms are not controlled with intranasal corticosteroids, 
adding montelukast did not offer any further benefit.
19
The anti-IgE antibody omalizumab may be efficacious, but it 
has not been shown to be superior to current allergic rhinitis 
treatments. Additionally, its high cost limits it use as a standard 
treatment.
1
Taken as a whole, intranasal corticosteroids seem to be the 
most effective in controlling nasal symptoms. The next most ef-
fective are oral and intranasal antihistamines. However, it is dif-
ficult to fully stratify medication classes because of the lack of 
sufficient uniform data. For instance, studies on antihistamines 
have excluded nasal congestion as a component of symptoms 
scores because they are not expected to improve this symptom. 
There may be some differences between seasonal and perenni-
al allergic rhinitis where, for some patients with perennial aller-
gic rhinitis, oral antihistamines may be as effective as nasal ste-
roids. Additionally, there is variable response to treatments 
among individuals.
3 Table 1 lists the effectiveness of different 
medications in symptom control of allergic rhinitis.
Immunotherapy
Subcutaneous immunotherapy (SCIT) has been shown to be 
effective in treating allergic rhinitis in patients with identifiable 
IgE mediated symptom triggers. It has some advantages over 
the above mention treatments. Effects can be sustained for years, 
and it may prevent the development of new allergen sensitivi-
ties or even asthma.
1 It is effective for not only control of allergic 
Table 1. Effectiveness in symptom control of various medications for allergic rhinitis
Symptom Oral antihistamine Nasal antihistamine Nasal steroids Nasal decongestant Nasal ipratropium bromide Nasal cromone
Rhinorrhea XX XX XXX – XX X
Sneezing XX XX XXX – – X
Nasal itching XX XX XXX – – X
Nasal congestion X X XXX XXXX – X
Ocularsymptoms XX – XX – – –
Adapted from van Cauwenberge et al.
2.
–, no effect; X: least; XXXX: most effective.Tran et al.
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rhinitis but also of allergic conjunctivitis and allergen induced 
asthma.
20 However, immunotherapy is underutilized with only 
2 to 3 million US individuals on SCIT of the estimated 55 mil-
lion people with allergic diseases.
21 In regard to specific inhaled 
allergens, evidence supports immunotherapy for pollens, ani-
mal dander, and dust mite. Large local reactions at the injection 
site are the most common adverse reaction. The risk of severe 
systemic reactions during subcutaneous immunotherapy is 
rare but present in less than 1% of those receiving standard im-
munotherapy. Near fatal events occurred at a rate of 5.4 per 
million injections. High ambient pollen levels and dosing er-
rors were the two main risk factors for such a reaction. It is ad-
vised that patients receive immunotherapy injections in a set-
ting with staff and equipment that can handle anaphylaxis, and 
that patient be observed for 30 minutes after each injection.
20 
Other disadvantages include injection discomfort, the frequen-
cy of shot visits, and the total cost. However, immunotherapy is 
the only treatment that can modify the disease. When the direct 
costs of symptomatically managed allergic rhinitis are compared 
to the cost of immunotherapy, the values are virtually the same.
8 
When indirect costs are factored, immunotherapy may be much 
more economical.
Subcutaneously is the most common way to deliver immuno-
therapy, but sublingual immunotherapy (SLIT) is also used. 
SLIT has been reported to cause oral itching and gastrointesti-
nal side effects, but in most studies, these rates seem to be the 
same as those observed in the placebo arm.
2 There is a lack of 
standardization in SLIT with timothy grass pollen extracts be-
ing the only commercially available therapy (Grazax by ALK-
Abelló Hørsholm. Denmark), and there are no SLIT therapies 
approved for the US by Food and Drug Administration. Advan-
tages of SLIT include an extremely low risk of anaphylaxis and 
the ability to begin therapy at the maintenance dose without a 
build-up phase.
22 SLIT for dust mite allergy has been specifical-
ly studied in the Korean population and found to be effective in 
reducing symptom scores.
23,24 Although anaphylaxis has not 
been noticed in studies on SLIT, there are case reports of ana-
phylaxis occurring during treatment, even with the first dose.
21 
SLIT is not as well established as SCIT, and further investigation 
is required to determine the optimal dose and patient selec-
tion.
2
A meta-analysis
25 done in January of 2010 reviewed the past 
20 years of studies on SLIT. Nineteen studies were included with 
a total of 2,971 study subjects. SLIT was found to improve both 
symptom scores and medication use for allergic rhinitis. It ap-
pears that a minimal dose of 450 μg of antigen per treatment 
was necessary and that using higher doses produced to benefit. 
Upon subgroup analysis, SLIT was far less effective in children 
than adults. This conclusion may have been confounded by the 
fact that most of the pediatric studies used doses of less than 
276 μg and the only pediatric study that showed statistically sig-
nificant benefit used a dose of 600 μg. Along these lines, the 
meta-analysis showed that SLIT tablets were more effective 
than drops in reducing symptom scores with the caveat that 
this difference is mostly noticed in pediatric studies where drops 
administered a lower dose than tablets. Additionally, some of 
the pediatric studies included allergens other than grass. Other 
pertinent conclusions were: that SLIT was more effective when 
given for 12 months or less compared to over 1 year of use; SLIT 
was not more effective for rhinitis control in allergic asthmatics 
than in subjects without allergic asthma; and the more impor-
tant that the length of treatment was the timing of beginning 
SLIT with initiation at least three months before grass season 
being optimal.
NONALLERGIC RHINITIS
Definition
Nonallergic rhinitis (NAR) is generally described as chronic 
nasal symptoms, such as obstruction and rhinorrhea that occur 
in relation to nonallergic, noninfectious triggers such as change 
in the weather, exposure to caustic odors or cigarette smoke, 
barometric pressure differences, etc. There is a lack of concom-
itant allergic disease, determined by negative skin prick test for 
relevant allergens and/or negative allergen-specific antibody 
tests.
26 The term vasomotor is often used which suggests in-
volvement of neural, glandular, and vascular pathways; howev-
er, this term is misleading because it implies a true understand-
ing of the underlying pathophysiology of the disease when this 
has not been definitively established.
27
In December of 2008, a roundtable conference which includ-
ed 8 expert physicians on rhinitis convened to establish a con-
sensus on the clinical definition of nonallergic vasomotor rhi-
nitis and to develop appropriate inclusion and exclusion crite-
ria for the enrollment of subjects in future clinical studies. From 
this NAR Consensus Panel Proceedings, there were at least 8 
subtypes that filled the criteria for NAR (Table 2).
1,26,28 Nonaller-
gic rhinopathy (formerly known as vasomotor rhinitis) accounts 
for the majority of NAR. It is a diverse group of patients that have 
chronic nasal symptoms with a lack of nasal eosinophilia and 
Table 2. Chronic rhinitis subtypes not associated with allergies, infection, or 
anatomic abnormalities
• Nonallergic rhinopathy, previously known as vasomotor rhinitis, or idio-
pathic nonallergic rhinitis
• Nonallergic rhinitis with eosinophilia
• Atrophic rhinitis
• Senile rhinitis
• Gustatory rhinitis
• Drug-induced rhinitis, including rhinitis medicamentosa
• Hormonal-induced rhinitis, including the rhinitis of pregnancy
• Cerebral spinal fluid leak
Adapted from Scarupa and Kaliner,
28 Wallace et al.
1, and Kaliner.
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an etiology that is neither immunologic nor due to infection. 
NAR with eosinophilia is characterized by patients who have 
year-round nasal symptoms but eosinophils are found on nasal 
smear though they lack positive skin tests and/or specific IgE 
antibodies in the serum. Atrophic rhinitis, as the name implies, 
refers to a chronic condition in which there is progressive atro-
phy of the nasal mucosa with crusting and dryness as the most 
prominent features. It is typically not inflammatory mediated.
1 
Senile rhinitis occurs most commonly in the elderly, presents 
mostly with watery rhinorrhea that may worsen after certain 
foods or environmental irritants. Gustatory rhinitis occurs after 
eating, especially hot or spicy foods. Rhinitis medicamentosa is 
included in drug-induced rhinitis, though a variety of medica-
tions have been implicated in causing chronic nasal congestion. 
Rhinitis medicamentosa most commonly occurs after repeated 
use of topical nasal decongestants such as oxymetzaoline or 
phenylephrine. Hormone induced rhinitis refers to the conges-
tion and nasal symptoms that occur in response to endogenous 
female hormones, such as seen in pregnancy. Cerebrospinal 
fluid (CSF) leak should be considered in patients with a history 
of cranio-facial trauma or past facial surgery that have persis-
tent, clear rhinorrhea.
26
Epidemiology
The exact prevalence and impact of NAR is not as established 
as it is for allergic rhinitis. It is estimated that it affects more than 
19 to 20 million patients in the United States, with vasomotor 
rhinitis being the most common subtype seen.
26,29 European 
studies evaluating the prevalence of NAR found that approxi-
mately 1 in 4 patients with nasal symptom complaints had 
“pure” NAR and it is estimated that 50 million Europeans have 
NAR, with a total prevalence of more than 200 million world-
wide.
26
With many subtypes of disease, the true economic burden of 
NAR is most likely grossly underestimated. Schatz et al.
29 re-
viewed the records of more than 1 million patients enrolled in 
the Kaiser Permanente Southern California Medical care pro-
gram from 2002-2005 and found that 15% had at least 1 encoun-
ter with the diagnosis. Another 14% received rhinitis medica-
tion with no medical encounter. They also found that patients 
from either group had significantly more health care visits per 
year for asthma (2-4 times as many), acute sinusitis (6-8 times 
as many) and all other diagnoses (almost twice as many). They 
also found that patients with rhinitis or treated for rhinitis had a 
higher prevalence of comorbid diseases such as asthma, acute 
and chronic sinusitis, nasal polyposis, conjunctivitis, acute oti-
tis media, chronic serous otitis media, sleep apnea, and fatigue. 
When reviewing the patient demographics, those with NAR 
were significantly older, mean age of 42.6 vs. 35.8 and more 
likely to be female than the patients with the diagnosis of aller-
gic rhinitis.
29
Importance of treatment
As Ledford
30 points out in his symposium on assessing the 
damage of inadequately diagnosed NAR, patients are often em-
pirically treated with oral second generation antihistamines, 
which are usually not sufficient in relieving their symptoms. 
The patients are then subjected to multiple rounds of treatment 
failures that lead to frustration towards seeking medical care 
and medication use. They must incur additional expenditures 
for doctor appointments, medication prescriptions, and lost 
time from work on top of their reduced quality of life. Besides 
this decrease in quality of life, untreated rhinitis does signifi-
cantly increase the risk of other comorbid conditions such as 
obstructive sleep apnea, fatigue, headache, malaise, poor appe-
tite and weakness. This effect is not limited to impaired work 
performance in adults but can also manifest as learning disabil-
ities, behavioral, and psychological effects in children. Children 
are also at risk for permanent facial changes from untreated rhi-
nitis such as increased facial length, retrognathic maxilla and 
mandible, and dental malocclusions from obstructed breath-
ing.
30
Beyond these physical and emotional impacts on patients 
there is also an economic burden from the incomplete diagno-
sis and treatment of rhinitis. Recent evidence shows that asth-
ma and rhinitis are often coexisting in atopic and nonatopic pa-
tients and that effective treatment of rhinitis frequently improves 
asthma.
31
Treatment
Avoidance
Avoidance of environmental triggers such as strong odors 
(perfumes, soaps, paint, etc.) and air pollutants (smoke fumes, 
tobacco smoke) that are respiratory irritants is recommended 
in those who find these worsen their rhinitis symptoms.
1,32
Antihistamines
Oral second generation antihistamines are not as effective in 
the treatment of NAR, though first generation oral antihista-
mines may haves some benefit due to anticholinergic activity.
33 
Topical antihistamines on the other hand have been found to 
be very effective for the overall treatment of NAR. Of the two 
topical antihistamines on the market in the United States (az-
elastine and olopatadine), azelastine is the only one that has 
been shown to be efficacious for nonallergic rhinitis.
1,32,34 Banov 
and Lieberman
32 evaluated the efficacy of the azelastine nasal 
spray in patients with nonallergic vasomotor rhinitis in a multi-
center, randomized, placebo-controlled trial and found a sig-
nificant improvement in total vasomotor rhinitis symptom 
scores (TVRSS) in those patients receiving azelastine (two sprays 
twice a day, 1.1 mg) versus placebo. In an open label, 2-week 
study with azelastine 2 sprays per nostril twice daily in patients 
with allergic rhinitis, mixed rhinitis, and nonallergic vasomotor 
rhinitis it was found that azelastine had improvement in control Tran et al.
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of all rhinitis symptoms including nasal congestion, postnasal 
drip, sneezing, and sleeping difficulty.
34 The previously men-
tioned metallic aftertaste that some patients describe with az-
elastine is dose-dependent and often dissipates over time.
33
Steroids
Intranasal corticosteroids have been found to be effective in 
nonallergic rhinitis, especially in vasomotor rhinitis and NA-
RES. Fluticasone propionate and beclomethasone are the only 
topical corticosteroids approved by the FDA in the US for the 
treatment of NAR. Clinically, there does not appear to be a dif-
ference between the intranasal steroids available at this time.
1 
Most are dosed twice daily and patients should be informed 
that it may take 24 to 72 hours before symptoms start to im-
prove though the onset of action is said to be from 3-12 hours.
33 
In a randomized, double-blind, placebo-controlled trial with 
983 patients with perennial nonallergic rhinitis performed by 
Webb et al.
35 patients received fluticasone propionate 200 mcg, 
400 mcg or placebo for 28 days. Primary endpoint was the mean 
change in total nasal symptom score (TNSS), which was a sum 
of patient ratings of nasal obstruction, postnasal drip, and rhi-
norrhea. Patients that were found to have NARES as well as 
those that did not, were shown to have similar statistically sig-
nificant improvement on either dose of fluticasone propionate 
compared with placebo.
33 However, there is a subgroup of NAR 
patients that fail to respond to intranasal corticosteroids and 
further study is warranted in these nonresponders.
36
Decongestants
Currently there are no specific studies looking at the effective-
ness of oral decongestants in the treatment of NAR. Thus, they 
should be considered adjunctive therapy, which is used on an 
as needed basis for nasal congestion that is not responsive to 
intranasal corticosteroids, topical antihistamines, or a combi-
nation of both.
Anticholinergics
The only topical anticholinergic medication approved in the 
United States for topical application is ipratropium bromide. 
Ipratropium bromide (0.03%) nasal spray is recommended 
when rhinorrhea is the predominant or only symptom, as in 
the case of gustatory rhinitis. From the updated rhinitis practice 
parameters, its use in combination with an intranasal cortico-
steroid is more effective than either drug alone for the treat-
ment of rhinorrhea. This is not only effective, but safe as well 
since there is not an increased incidence of adverse events.
1
Nasal saline
Nasal lavage with saline solution has also been found to be a 
helpful alone or as an adjuvant therapy in patients with chronic 
rhinorrhea and rhinosinusitis.
1 It is best performed immediate-
ly prior to intranasal corticosteroids or azelastine and may be 
especially helpful in reducing postnasal drip, sneezing, and 
congestion.
37 A 2007 Cochrane database review found 8 ran-
domized controlled trials in which saline was evaluated in 
comparison with either no treatment, placebo, as an adjunct to 
other treatments or against treatments. There was no evidence 
that saline alone was beneficial in the treatment of chronic rhi-
nosinusitis nor was it more effective than an intranasal cortico-
steroid. However, there was favorable evidence for saline as an 
adjunct treatment. The final conclusion was that saline irriga-
tions are a well tolerated with very minor side effects that can 
be included as a treatment adjunct for chronic rhinosinusitis 
symptoms.
38 In a prospective, randomized controlled trial with 
121 adults with chronic nasal and sinus symptoms, Pynnonen 
et al.
39 looked to determine if isotonic sodium chloride nasal ir-
rigations performed with large volume and low positive pres-
sure was more effective than saline sprays at improving quality 
of life and decreasing medication use. The primary outcomes 
measured were a change in symptom severity measure by a 
mean 20-item Sino-Nasal Outcome Test (SNOT-20) score, med-
ication use, and symptom frequency. The outcomes were looked 
at 3 different time points (2, 4, and 8 weeks). The high volume, 
low positive pressure group had lower SNOT-20 scores at all 
time points. They also had a lower frequency of “often or al-
ways” nasal symptom reporting compared to the spray group 
(40% of subjects versus 61%). A significant difference was not 
found in sinus medication use in either group.
39
The exact mechanism of how saline is helpful in allergic rhini-
tis and rhinosinusitis has not been confirmed but it is postulat-
ed that it may improve mucus clearance; remove antigen, in-
flammatory mediators, or biofilm; enhance ciliary beat; and 
protect the nasal mucosa. Side effects from its use are typically 
minor and consist of burning, irritation, and nausea. There is 
not an established consensus regarding method of delivery, 
volume to use, ratio of isotonic to hypertonic, or frequency.
1
Investigational therapies
1. Capsaicin
Capsaicin is the chemical contained within the oil of Capsi-
cum pepper and while it is initially irritating to the applied area, 
it eventually desensitizes the sensory neural fibers. It has been 
used intranasal to try and decrease nasal hyperreactivity re-
sponsible for rhinorrhea, sneezing, and congestion.
37 A place-
bo-controlled studies using intranasal capsaicin in patient with 
nonallergic, noninfectious perennial rhinitis found a significant 
and long-term reduction in the visual analogue scale (VAS) 
scores in the treatment group but no difference objective mea-
sures of inflammation such as concentration of leukotriene C4/
D4/E4, prostaglandin D2, and tryptase.
40
2. Silver nitrate
Topically applied silver nitrate was found to be effective in a 
trial comparing silver nitrate, flunisolide, and placebo in pa-Management of Rhinitis: Allergic and Non-Allergic
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tients with NAR. Improvement was found in patient reported 
rhinorrhea, sneezing and nasal congestion.
41 Two prospective 
studies in patients with vasomotor rhinitis also found signifi-
cant improvement in nasal symptoms.
42,43
3. Acupuncture
From a systematic review of complementary and alternative 
medicine for rhinitis and asthma published in the Journal of Al-
lergy and Clinical Immunology in 2006, the majority of studies 
on acupuncture were in allergic rhinitis and were not random-
ized, controlled, or descriptive. There was 1 nonrandomized 
study in NAR that showed no difference in nasal airflow and 
symptoms between acupuncture and electrostimulation.
44 
However, in 2009, a random, placebo-controlled study by Fleck-
enstein et al.
45 was published that showed a significant change 
in nasal sickness score (NSS, max 27 points) in patients with va-
somotor rhinitis treated with acupuncture versus those who had 
sham laser acupuncture treatment. The treatment group had a 
NSS that went from 9.3±3.89 to 4.1±3.2 (P<0.001) while the 
sham groups NSS went from 5.6±2.74 to 3.7±2.4.
45
Surgery
After 6-12 months of failed medical therapy (intranasal corti-
costeroid with azelastine and/or decongestants and/or ipratro-
pium bromide) then surgical options may be considered. It 
may also be indicated if the patient has comorbid conditions 
such as nasal obstruction from severe nasal septal deviation or 
inferior turbinate hypertrophy, adenoidal hypertrophy, or re-
fractory sinusitis.
1 Treatment similarities and differences in al-
lergy and nonallergic rhinitis are outlined in Table 3.
SUMMARY
Rhinitis is a prevalent disease worldwide that causes a signifi-
cant impact on patient quality of life, can affect multiple co-
morbid conditions, and is a substantial economic burden on 
society. It is important to note that a majority of rhinitis patients 
experience significant non-allergic triggers and thus may non-
allergic or mixed (allergic and non-allergic) rhinitis. An im-
proved consensus criterion for defining rhinitis subtypes is es-
sential. This will allow for better understanding the prevalence 
and epidemiology of chronic rhinitis subtypes and for selecting 
the appropriate study populations to investigate mechanisms 
and specific therapies of these disorders.
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